PREMAL LULLA to Leukemia, Myeloid, Acute
This is a "connection" page, showing publications PREMAL LULLA has written about Leukemia, Myeloid, Acute.
Connection Strength
1.897
-
Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021 05 13; 137(19):2585-2597.
Score: 0.489
-
Myelodysplastic syndrome and immunotherapy novel to next in-line treatments. Hum Vaccin Immunother. 2021 08 03; 17(8):2602-2616.
Score: 0.488
-
Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. Cancer J. 2019 May/Jun; 25(3):199-207.
Score: 0.425
-
Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia. Blood. 2024 04 25; 143(17):1726-1737.
Score: 0.150
-
The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature. Blood. 2024 03 28; 143(13):1269-1281.
Score: 0.149
-
CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia. Mol Ther. 2019 01 02; 27(1):272-280.
Score: 0.102
-
Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213.
Score: 0.094